{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:07:08Z","timestamp":1790662028627,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Octapharma provided a grant for writing the article. Octapharma did not have any influence on the contents for which the authors are entirely responsible."},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40263-021-00863-4","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T21:26:13Z","timestamp":1634419573000},"page":"1173-1188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology"],"prefix":"10.1007","volume":"35","author":[{"given":"Fabian","family":"Szepanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Mausberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"issue":"Suppl 2","key":"863_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-018-0290-5","volume":"14","author":"C McCusker","year":"2018","unstructured":"McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):61.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"863_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10875-007-9103-1","volume":"27","author":"JM Boyle","year":"2007","unstructured":"Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497\u2013502.","journal-title":"J Clin Immunol"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","volume":"10","author":"A Aiello","year":"2019","unstructured":"Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and Its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol. 2019;10:2247.","journal-title":"Front Immunol"},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"issue":"3","key":"863_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2323","volume":"34","author":"V Friman","year":"2016","unstructured":"Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121\u201332.","journal-title":"Hematol Oncol"},{"issue":"5","key":"863_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.pcl.2019.06.009","volume":"66","author":"H Axelrod","year":"2019","unstructured":"Axelrod H, Adams M. Biologic agents and secondary immune deficiency. Pediatr Clin N Am. 2019;66(5):1007\u201320.","journal-title":"Pediatr Clin N Am"},{"issue":"11","key":"863_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458516681198","volume":"23","author":"JM Wijnands","year":"2017","unstructured":"Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler. 2017;23(11):1506\u201316.","journal-title":"Mult Scler"},{"issue":"2","key":"863_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184\u201391.","journal-title":"JAMA Neurol"},{"issue":"4","key":"863_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742\u201368.","journal-title":"Neuron"},{"issue":"10","key":"863_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557\u201367.","journal-title":"Nat Clin Pract Neurol"},{"issue":"12","key":"863_CR11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","volume":"20","author":"JJ Sabatino Jr","year":"2019","unstructured":"Sabatino JJ Jr, Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20(12):728\u201345.","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"863_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrneurol.2017.123","volume":"13","author":"YA Rajabally","year":"2017","unstructured":"Rajabally YA, Stettner M, Kieseier BC, Hartung HP, Malik RA. CIDP and other inflammatory neuropathies in diabetes-diagnosis and management. Nat Rev Neurol. 2017;13(10):599\u2013611.","journal-title":"Nat Rev Neurol"},{"key":"863_CR13","doi-asserted-by":"crossref","unstructured":"Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al. Targeting B cells to modify MS, NMOSD, and MOGAD: part 2. Neurol Neuroimmunol Neuroinflamm. 2020;16;8(1):e919.","DOI":"10.1212\/NXI.0000000000000919"},{"issue":"1","key":"863_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X, et al. Role of b cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13\u201323.","journal-title":"Ann Neurol"},{"issue":"1","key":"863_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83(1):13\u201326.","journal-title":"Ann Neurol"},{"issue":"7","key":"863_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"175628641877302","DOI":"10.1177\/1756286418773025","volume":"11","author":"P Mulero","year":"2018","unstructured":"Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11:1756286418773025.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"863_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1352458514561911","volume":"21","author":"SL Hauser","year":"2015","unstructured":"Hauser SL. The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler. 2015;21(1):8\u201321.","journal-title":"Mult Scler"},{"issue":"5","key":"863_CR19","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/eji.201470045","volume":"44","author":"F Hoffmann","year":"2014","unstructured":"Hoffmann F, Meinl E. B cells in multiple sclerosis: good or bad guys?: an article for 28 May 2014-World MS Day 2014. Eur J Immunol. 2014;44(5):1247\u201350.","journal-title":"Eur J Immunol"},{"issue":"6","key":"863_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"issue":"15 Supplement","key":"863_CR21","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1212\/WNL.96.15_supplement.4494","volume":"96","author":"L Steinman","year":"2021","unstructured":"Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, et al. Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: results of the Phase 3 ULTIMATE I and II trials (4494). Neurology. 2021;96(15 Supplement):4494.","journal-title":"Neurology"},{"issue":"6","key":"863_CR22","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","volume":"176","author":"A Crawford","year":"2006","unstructured":"Crawford A, Macleod M, Schumacher T, Corlett L, Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol. 2006;176(6):3498\u2013506.","journal-title":"J Immunol"},{"issue":"4","key":"863_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460\u201371.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"863_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1\u20132):63\u201370.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"863_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"863_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"863_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613\u201320.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"863_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","volume":"27","author":"I Avivi","year":"2013","unstructured":"Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev. 2013;27(5):217\u201323.","journal-title":"Blood Rev"},{"issue":"3","key":"863_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.humimm.2019.01.001","volume":"80","author":"Q Chen","year":"2019","unstructured":"Chen Q, Yuan S, Sun H, Peng L. CD3(+)CD20(+) T cells and their roles in human diseases. Hum Immunol. 2019;80(3):191\u20134.","journal-title":"Hum Immunol"},{"issue":"1","key":"863_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awy301","volume":"142","author":"MR von Essen","year":"2019","unstructured":"von Essen MR, Ammitzboll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142(1):120\u201332.","journal-title":"Brain"},{"issue":"9","key":"863_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: .5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"863_CR32","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625\u201332.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"863_CR33","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","volume":"5","author":"A Marcinno","year":"2018","unstructured":"Marcinno A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e498.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"863_CR34","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115\u201322.","journal-title":"J Neurol"},{"key":"863_CR35","first-page":"65","volume":"279399","author":"T Derfuss","year":"2019","unstructured":"Derfuss T, Weber MS, Hughes R, Wang Q, Sauter A, Koendgen H, et al. Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. ECTRIMS Online Library. 2019;279399:65.","journal-title":"ECTRIMS Online Library."},{"issue":"20","key":"863_CR36","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074\u201381.","journal-title":"Neurology"},{"issue":"11","key":"863_CR37","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/art.22211","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612\u201322.","journal-title":"Arthritis Rheum"},{"issue":"S2","key":"863_CR38","first-page":"85","volume":"22","author":"J de Seze","year":"2020","unstructured":"de Seze J, Bar-Or AJC, Cross A-H, Kappos L, Selmaj K, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis patients from the phase 3 ASCLEPIOS I and II Trials. Int J MS Care. 2020;22(S2):85.","journal-title":"Int J MS Care."},{"issue":"3","key":"863_CR39","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","volume":"111","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study. Blood. 2008;111(3):1094\u2013100.","journal-title":"Blood"},{"issue":"13","key":"863_CR40","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","volume":"16","author":"MH van Oers","year":"2015","unstructured":"van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16(13):1370\u20139.","journal-title":"Lancet Oncol"},{"issue":"16 Supplement","key":"863_CR41","doi-asserted-by":"crossref","first-page":"S24.003","DOI":"10.1212\/WNL.88.16_supplement.S24.003","volume":"88","author":"P Smith","year":"2017","unstructured":"Smith P, Huck C, Schmid C, Baumgartner R, Stuber N, Theil D, et al. Ofatumumab differs from rituximab by effectively targeting lymph node B cells and achieving faster post-treatment repletion (S24.03). Neurology. 2017;88(16 Supplement):S24.003.","journal-title":"Neurology"},{"issue":"3","key":"863_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cei.13208","volume":"194","author":"Z Li","year":"2018","unstructured":"Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194(3):295\u2013314.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"863_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","volume":"83","author":"GA Hill-Cawthorne","year":"2012","unstructured":"Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"863_CR44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","volume":"81","author":"CL McCarthy","year":"2013","unstructured":"McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872\u20136.","journal-title":"Neurology"},{"issue":"2","key":"863_CR45","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1212\/NXI.0000000000000654","volume":"7","author":"N Mohn","year":"2020","unstructured":"Mohn N, Pfeuffer S, Ruck T, Gross CC, Skripuletz T, Klotz L, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e654.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"863_CR46","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1177\/1352458518796675","volume":"25","author":"S Wray","year":"2019","unstructured":"Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019;25(12):1605\u201317.","journal-title":"Mult Scler"},{"issue":"7","key":"863_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","volume":"17","author":"AR Buonomo","year":"2018","unstructured":"Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709\u201317.","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"863_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","volume":"73","author":"PL McCormack","year":"2013","unstructured":"McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013;73(13):1463\u201381.","journal-title":"Drugs"},{"key":"863_CR49","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3389\/fimmu.2018.01560","volume":"9","author":"L Lohmann","year":"2018","unstructured":"Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, et al. Immune cell profiling during switching from natalizumab to fingolimod reveals differential effects on systemic immune-regulatory networks and on trafficking of non-T cell populations into the cerebrospinal fluid-results from the ToFingo successor study. Front Immunol. 2018;9:1560.","journal-title":"Front Immunol"},{"issue":"11","key":"863_CR50","doi-asserted-by":"publisher","first-page":"e47578","DOI":"10.1371\/journal.pone.0047578","volume":"7","author":"L Bornsen","year":"2012","unstructured":"Bornsen L, Christensen JR, Ratzer R, Oturai AB, Sorensen PS, Sondergaard HB, et al. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. PLoS ONE. 2012;7(11):e47578.","journal-title":"PLoS ONE"},{"issue":"11","key":"863_CR51","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1177\/1352458513477229","volume":"19","author":"RC Selter","year":"2013","unstructured":"Selter RC, Biberacher V, Grummel V, Buck D, Eienbroker C, Oertel WH, et al. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler. 2013;19(11):1454\u201361.","journal-title":"Mult Scler"},{"issue":"11","key":"863_CR52","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/archneurol.2011.238","volume":"68","author":"C Saure","year":"2011","unstructured":"Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, Cadeddu RP, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011;68(11):1428\u201331.","journal-title":"Arch Neurol"},{"issue":"3","key":"863_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","volume":"42","author":"R Planas","year":"2012","unstructured":"Planas R, Jelcic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol. 2012;42(3):790\u20138.","journal-title":"Eur J Immunol"},{"issue":"1\u20132","key":"863_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","volume":"341","author":"M Kaufman","year":"2014","unstructured":"Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1\u20132):22\u20137.","journal-title":"J Neurol Sci"},{"issue":"6","key":"863_CR55","doi-asserted-by":"publisher","first-page":"e621","DOI":"10.1212\/NXI.0000000000000621","volume":"6","author":"F Largey","year":"2019","unstructured":"Largey F, Jelcic I, Sospedra M, Heesen C, Martin R, Jelcic I. Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e621.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"863_CR56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med"},{"issue":"9","key":"863_CR57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"15 Supplement","key":"863_CR58","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1212\/WNL.94.15_supplement.2815","volume":"94","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Kappos L, Berger J, Cutter G, Fox R, Wiendl H, et al. Updated incidence of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and its relationship with natalizumab exposure over time (2815). Neurology. 2020;94(15 Supplement):2815.","journal-title":"Neurology"},{"issue":"20","key":"863_CR59","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"6","key":"863_CR60","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/cid\/cit376","volume":"57","author":"AJ Fine","year":"2013","unstructured":"Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis. 2013;57(6):849\u201352.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"863_CR61","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883\u201397.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"863_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","volume":"19","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19(4):336\u201347.","journal-title":"Lancet Neurol"},{"issue":"4","key":"863_CR63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1352458513500551","volume":"20","author":"G Francis","year":"2014","unstructured":"Francis G, Kappos L, O\u2019Connor P, Collins W, Tang D, Mercier F, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471\u201380.","journal-title":"Mult Scler"},{"issue":"23","key":"863_CR64","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.0000000000001049","volume":"83","author":"C Warnke","year":"2014","unstructured":"Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, et al. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology. 2014;83(23):2153\u20137.","journal-title":"Neurology"},{"issue":"9","key":"863_CR65","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458517713147","volume":"23","author":"M Ghadiri","year":"2017","unstructured":"Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, et al. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Mult Scler. 2017;23(9):1225\u201332.","journal-title":"Mult Scler"},{"issue":"1","key":"863_CR66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clim.2010.06.005","volume":"137","author":"TA Johnson","year":"2010","unstructured":"Johnson TA, Shames I, Keezer M, Lapierre Y, Haegert DG, Bar-Or A, et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol. 2010;137(1):15\u201320.","journal-title":"Clin Immunol"},{"key":"863_CR67","doi-asserted-by":"publisher","first-page":"175628641987834","DOI":"10.1177\/1756286419878340","volume":"12","author":"G Zoehner","year":"2019","unstructured":"Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, et al. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019;12:1756286419878340.","journal-title":"Ther Adv Neurol Disord"},{"key":"863_CR68","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.msard.2020.101963","volume":"40","author":"E Signoriello","year":"2020","unstructured":"Signoriello E, Bonavita S, Sinisi L, Russo CV, Maniscalco GT, Casertano S, et al. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. Mult Scler Relat Disord. 2020;40:101963.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"863_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.22352","volume":"69","author":"M Mehling","year":"2011","unstructured":"Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408\u201313.","journal-title":"Ann Neurol"},{"issue":"3","key":"863_CR70","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1212\/NXI.0000000000000028","volume":"1","author":"M Mehling","year":"2014","unstructured":"Mehling M, Eichin D, Hafner P, Honger G, Kappos L, Hess C. Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS. Neurol Neuroimmunol Neuroinflamm. 2014;1(3):e28.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"863_CR71","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872\u20139.","journal-title":"Neurology"},{"issue":"14","key":"863_CR72","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","volume":"76","author":"MC Kowarik","year":"2011","unstructured":"Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kumpfel T, Buck D, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011;76(14):1214\u201321.","journal-title":"Neurology"},{"issue":"5","key":"863_CR73","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"863_CR74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"6","key":"863_CR75","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356.","journal-title":"Lancet Neurol"},{"issue":"1","key":"863_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31\u20139.","journal-title":"JAMA Neurol"},{"key":"863_CR77","doi-asserted-by":"publisher","first-page":"175628641987832","DOI":"10.1177\/1756286419878324","volume":"12","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324.","journal-title":"Ther Adv Neurol Disord"},{"key":"863_CR78","unstructured":"Fox R CB, Greenberg B, Hemmer B, Ward BJ, Ontaneda D, Moore A, Zhang Y, Sullivan R, Girase P, Hach T, Berger JR. Update on the risk estimates of progressive multifocal leukoencephalopathy related to fingolimod. MSVirtual 2020. 2020; Abstract FC02.02."},{"issue":"4","key":"863_CR79","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","volume":"3","author":"L Kappos","year":"2014","unstructured":"Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Disord. 2014;3(4):494\u2013504.","journal-title":"Mult Scler Relat Disord."},{"issue":"18","key":"863_CR80","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s40265-019-01229-3","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2019;79(18):1965\u201376.","journal-title":"Drugs"},{"issue":"12","key":"863_CR81","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"863_CR82","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"3","key":"863_CR83","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Chang I, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139.","journal-title":"Neurol Clin Pract."},{"key":"863_CR84","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.freeradbiomed.2019.07.005","volume":"141","author":"AK Herrmann","year":"2019","unstructured":"Herrmann AK, Wullner V, Moos S, Graf J, Chen J, Kieseier B, et al. Dimethyl fumarate alters intracellular Ca(2+) handling in immune cells by redox-mediated pleiotropic effects. Free Radic Biol Med. 2019;141:338\u201347.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"863_CR85","doi-asserted-by":"publisher","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","volume":"92","author":"D Mehta","year":"2019","unstructured":"Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019;92(15):e1724\u201338.","journal-title":"Neurology"},{"issue":"3","key":"863_CR86","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1212\/NXI.0000000000000340","volume":"4","author":"M Ghadiri","year":"2017","unstructured":"Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm. 2017;4(3):e340.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"8","key":"863_CR87","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1352458515608961","volume":"22","author":"EE Longbrake","year":"2016","unstructured":"Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler. 2016;22(8):1061\u201370.","journal-title":"Mult Scler"},{"key":"863_CR88","first-page":"135245852093728","volume":"27","author":"EE Longbrake","year":"2020","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2020;27:1352458520937282.","journal-title":"Mult Scler"},{"issue":"1","key":"863_CR89","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","volume":"5","author":"C von Hehn","year":"2018","unstructured":"von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e409.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"863_CR90","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12883-021-02165-0","volume":"21","author":"EA Vola","year":"2021","unstructured":"Vola EA, Petracca M, Cocozza S, De Angelis M, Carotenuto A, Pontillo G, et al. Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions. BMC Neurol. 2021;21(1):146.","journal-title":"BMC Neurol"},{"issue":"6","key":"863_CR91","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1056\/NEJMc1506151","volume":"373","author":"D Balak","year":"2015","unstructured":"Balak D, Hajdarbegovic E. PML in patients treated with dimethyl fumarate. N Engl J Med. 2015;373(6):582\u20133.","journal-title":"N Engl J Med"},{"issue":"4","key":"863_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","volume":"87","author":"K Lehmann-Horn","year":"2016","unstructured":"Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, et al. PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology. 2016;87(4):440\u20131.","journal-title":"Neurology"},{"issue":"10","key":"863_CR93","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","volume":"13","author":"H Wiendl","year":"2017","unstructured":"Wiendl H. Cladribine\u2014an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol. 2017;13(10):573\u20134.","journal-title":"Nat Rev Neurol"},{"key":"863_CR94","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"863_CR95","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"863_CR96","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604.","journal-title":"Mult Scler"},{"issue":"5","key":"863_CR97","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","volume":"265","author":"B Ceronie","year":"2018","unstructured":"Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265(5):1199\u2013209.","journal-title":"J Neurol"},{"key":"863_CR98","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","volume":"27","author":"K Rejdak","year":"2019","unstructured":"Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117\u201320.","journal-title":"Mult Scler Relat Disord."},{"key":"863_CR99","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"S Cook","year":"2019","unstructured":"Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157\u201367.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"863_CR100","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/ACI.0000000000000485","volume":"18","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Robertson NP, Jolles S. Secondary antibody deficiency in neurology. Curr Opin Allergy Clin Immunol. 2018;18(6):481\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"863_CR101","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169.","journal-title":"JAMA Netw Open"},{"issue":"373","key":"863_CR102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","volume":"15","author":"M Cohen","year":"2017","unstructured":"Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017;15(373):335\u20138.","journal-title":"J Neurol Sci"},{"issue":"9","key":"863_CR103","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110\u20137.","journal-title":"JAMA Neurol"},{"issue":"2","key":"863_CR104","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","volume":"73","author":"H Griffiths","year":"1989","unstructured":"Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989;73(2):366\u20138.","journal-title":"Blood"},{"issue":"14","key":"863_CR105","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","volume":"319","author":"RP Gale","year":"1988","unstructured":"Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic L, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"863_CR106","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","volume":"88","author":"H Chapel","year":"1994","unstructured":"Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol. 1994;88(1):209\u201312.","journal-title":"Br J Haematol"},{"issue":"6","key":"863_CR107","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13223","volume":"102","author":"IK Na","year":"2019","unstructured":"Na IK, Buckland M, Agostini C, Edgar JDM, Friman V, Michallet M, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102(6):447\u201356.","journal-title":"Eur J Haematol"},{"issue":"9","key":"863_CR108","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","volume":"12","author":"C Agostini","year":"2016","unstructured":"Agostini C, Blau IW, Kimby E, Plesner T. Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014an expert opinion. Expert Rev Clin Immunol. 2016;12(9):921\u20136.","journal-title":"Expert Rev Clin Immunol"},{"key":"863_CR109","unstructured":"European Medicines Agency: Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf. 2019. Accessed 30 July 2021."},{"issue":"2","key":"863_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","volume":"179","author":"S Jolles","year":"2015","unstructured":"Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146\u201360.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"863_CR111","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","volume":"32","author":"H Abolhassani","year":"2012","unstructured":"Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180\u201392.","journal-title":"J Clin Immunol"},{"key":"863_CR112","first-page":"CD006501","volume":"4","author":"P Raanani","year":"2008","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;4:CD006501.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"863_CR113","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000064258","volume":"128","author":"T Kawano","year":"2002","unstructured":"Kawano T, Matsuse H, Obase Y, Kondo Y, Machida I, Tomari S, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol. 2002;128(3):240\u20133.","journal-title":"Int Arch Allergy Immunol"},{"key":"863_CR114","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","volume":"10","author":"T Zrzavy","year":"2019","unstructured":"Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, et al. Vaccination in multiple sclerosis: friend or foe? Front Immunol. 2019;10:1883.","journal-title":"Front Immunol"},{"key":"863_CR115","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","volume":"59","author":"TC Heineman","year":"2019","unstructured":"Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019;59:42\u20138.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"863_CR116","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"issue":"7798","key":"863_CR117","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"key":"863_CR118","doi-asserted-by":"crossref","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.","journal-title":"Ther Adv Neurol Disord"},{"key":"863_CR119","doi-asserted-by":"publisher","first-page":"175628642199370","DOI":"10.1177\/1756286421993701","volume":"14","author":"M Fleischer","year":"2021","unstructured":"Fleischer M, Kohrmann M, Dolff S, Szepanowski F, Schmidt K, Herbstreit F, et al. Observational cohort study of neurological involvement among patients with SARS-CoV-2 infection. Ther Adv Neurol Disord. 2021;14:1756286421993701.","journal-title":"Ther Adv Neurol Disord"},{"key":"863_CR120","doi-asserted-by":"crossref","unstructured":"Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020;4;7(5):e787.","DOI":"10.1212\/NXI.0000000000000787"},{"issue":"9","key":"863_CR121","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079\u201388.","journal-title":"JAMA Neurol"},{"issue":"6","key":"863_CR122","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00415-020-10015-1","volume":"268","author":"V Mantero","year":"2021","unstructured":"Mantero V, Abate L, Basilico P, Balgera R, Salmaggi A, Nourbakhsh B, et al. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J Neurol. 2021;268(6):2023\u20135.","journal-title":"J Neurol"},{"key":"863_CR123","doi-asserted-by":"crossref","unstructured":"Capone F, Ferraro E, Motolese F, Di Lazzaro V. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. J Neurol. 2021;268(9):3132\u20134.","DOI":"10.1007\/s00415-021-10446-4"},{"issue":"4","key":"863_CR124","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780\u20139.","journal-title":"Ann Neurol"},{"issue":"7","key":"863_CR125","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","volume":"41","author":"G Dalla Costa","year":"2020","unstructured":"Dalla Costa G, Leocani L, Montalban X, Guerrero AI, Sorensen PS, Magyari M, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020;41(7):1647\u201350.","journal-title":"Neurol Sci"},{"issue":"420","key":"863_CR126","doi-asserted-by":"publisher","first-page":"117230","DOI":"10.1016\/j.jns.2020.117230","volume":"15","author":"S Kovvuru","year":"2021","unstructured":"Kovvuru S, Nalleballe K, Onteddu SR, Sharma R, Jasti M, Kapoor N, et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021;15(420):117230.","journal-title":"J Neurol Sci"},{"key":"863_CR127","doi-asserted-by":"crossref","unstructured":"Monschein T, Hartung HP, Zrzavy T, Barnett M, Boxberger N, Berger T, et al. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry. 2021;92(10):1033\u201343.","DOI":"10.1136\/jnnp-2021-326839"},{"key":"863_CR128","doi-asserted-by":"crossref","unstructured":"Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol. 2021;1\u20138.","DOI":"10.1007\/s00415-021-10545-2"},{"issue":"9","key":"863_CR129","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","volume":"16","author":"C Korsukewitz","year":"2020","unstructured":"Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. Nat Rev Neurol. 2020;16(9):493\u2013505.","journal-title":"Nat Rev Neurol"},{"key":"863_CR130","doi-asserted-by":"publisher","first-page":"102787","DOI":"10.1016\/j.msard.2021.102787","volume":"49","author":"KR Cotchett","year":"2021","unstructured":"Cotchett KR, Dittel BN, Obeidat AZ. Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;49:102787.","journal-title":"Mult Scler Relat Disord."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00863-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:54:22Z","timestamp":1725933262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00863-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":130,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00863-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"13 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Octapharma provided a grant for writing this review article. Octapharma did not have any influence on the contents, for which the authors are entirely responsible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F. Szepanowski has no conflicts of interest. C. Warnke has received institutional support from Novartis, Biogen, Alexion, Janssen, and Roche. G. Meyer zu H\u00f6rste served on scientific advisory boards for LFB and received speaker honoraria from Alexion. A. Mausberg has no conflicts of interest. H-P. Hartung received personal fees for consulting, serving on steering and data monitoring committees from Bayer Healthcare, Biogen, Celgene Receptos, CSL Behring, GeNeuro, MedImmune, Merck, Novartis, Octapharma, Roche, Sanofi Genzyme, Teva. C. Kleinschnitz has received remuneration for lectures and advisory boards from Alexion, Almirall, Amgen, Amicus, Bayer, Biogen, Biotronik, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, CSL Behring, Daiichi Sankyo, Desitin, Eisai, Ever Pharma, GE Healthcare, MedDay Pharmaceuticals, Merck Serono, Mylan\/Viatris, Novartis, Pfizer, Roche, Sanofi-Genzyme, Siemens, STADA, Stago, Teva. C. Kleinschnitz owns shares: Sanofi < 30.000 \u20ac. Biontec < 30.000 \u20ac. M. Stettner served on the scientific advisory boards and\/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec, Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors take responsibility for the integrity and accuracy of data interpretation and statements. Review concept and design: MS, FS. Drafting of the manuscript: MS, FS. Critical revision of the manuscript for intellectual content: MS, CW, GMH, H-PH, CK. All authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}